Submit Manuscript    >>    Login | Register

SGLT2 Inhibitors: A Game-Changer for Patients with Atrial Fibrillation?

We read with great interest the recently published article by Haloot et al. assessing the effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on the risk of adverse cardiovascular events in patients with atrial fibrillation (AF). This interesting observational study used data from a large multi-center dataset of electronic health records to provide valuable insight into the cardiovascular benefits of SGLT2 inhibitors in an AF population.

Credits: Alireza Oraii, Jeff S. Healey, Arjun K. Pandey, William F. McIntyre

Biosense Webster
event date
Introduction to AFib
Ablation Specialist

View Ablation Specialists